NEW YORK, NY, September 5, 2018 (GLOBE NEWSWIRE) — Radiance Bio, Inc., private company, (the “Company,” or Radiance), provides its corporate strategy for the financial community. Radiance is planning to develop a BCMA targeted CAR T-Cell Therapy for Multiple Myeloma, and apply for an Investigational New Drug application (IND) to conduct a Phase I clinical trials in the United States and Europe.

Multiple Myeloma

Myeloma is a cancer of plasma cells, which are a type of white blood cells. Myeloma is the 2nd most common type of blood cancer. There are over 95,000 people in the United States being treated for Myeloma, and nearly 35,000 new cases annually. Worldwide there are nearly 230,000 people with myeloma, and 115,000 new cases annually. Despite advances in the treatment of multiple myeloma in the past decade, it remains an incurable disease. Patients with relapsed or refractory Multiple Myeloma after ≥3 prior therapies, have a median survival of 8 months.

BCMA CAR T-Cell

B-cell maturation antigen (BCMA), a cell surface receptor expressed universally on myeloma cells, is currently being investigated as a potential target in Multiple Myeloma. Chimeric antigen receptor modified T cells (CAR T cells) have been highly successful in other hematologic malignancies, including leukemia and lymphoma. A BCMA targeted CAR T Therapy (bb2121) chimeric antigen receptor (CAR) T-cell therapy engineered to target B-cell maturation antigen (BCMA) holds great promise for the treatment of multiple myeloma (MM). In a recent trial conducted by Blue Bird and Celgene, 22 evaluable patients who received bb2121 CAR T cells in a Phase I trial, had objective response rate of 95%, and 50.0% of individuals achieved complete response.

Partnering Opportunities

Radiance is seeking to engage in partnering opportunities with pharmaceutical companies in the Unites States and abroad. A competitor, Legend Biotech USA Inc., a subsidiary of Genscript Biotech Corporation (“Legend”), entered into a worldwide collaboration and license agreement with Janssen Pharmaceutical Company, subsidiary of Johnson & Johnson, to develop and commercialize a BCMA targeted CAR T-cell drug called LCAR-B38M for profit-split arrangement. Janssen agreed to make to Legend an upfront payment of $350 million and additional payments based upon the achievement of certain development, regulatory and sales milestones.

Capital Raising Strategy

Radiance has launched a private offering under Regulation D Rule 506© under the JOBS Act to raise equity capital that will allow it to conduct clinical trials in the United States and overseas. The Company plans to incorporate a European subsidiary to apply for financial incentives to conduct trials in Europe, and has planned the same in Asia.

About Radiance Bio, Inc.

Radiance Bio is privately held company developing CAR T-Cell Therapy and gene therapy. The founders of Radiance Bio founded Aurora Biopharma that is developing HER2 targeted CAR T-cell therapy for Glioblastoma and Sarcoma.

Cautionary Note on Forward-Looking Statements

This press release and any statements of representatives and partners of Radiance Bio, Inc. (the “Company”) related thereto contain, or may contain, among other things, certain “forward-looking statements” within the meaning of the U.S. federal securities laws. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company’s plans, objectives, projections, expectations and intentions and other statements identified by words such as “projects,” “may,” “will,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential” or similar expressions. These statements are based upon the current beliefs and expectations of the Company’s management. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors, many of which are beyond the Company’s control. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

For media inquiries, please contact:

Radiance Bio, Inc.

Tel: (646) 975-2119

For further information please visit www.Radiancebio.com.

SOURCE Radiance Bio, Inc.